Marksans Pharma Ltd

- The document does not mention any current or planned fundraising through debt or equity. - It states the company continues to remain debt-free, with a cash balance of Rs. 666.5 crore as of September 30, 2025. - There is a focus on internal cash flows and budgets for CAPEX, such as a planned CAPEX of about Rs. 100 crores in 2026 for capacity expansion. - No specific plans for raising funds via equity or debt are discussed. - Future investments, including expansions and acquisitions, appear to be funded through cash on hand and internal accruals.

- Planned CAPEX of around ₹100 crores in 2026 to expand tablet capacity at the old Goa plant from 700-800 million to 1.2-1.3 billion tablets per month, also tripling soft gel capacity. - Expansion focused on acquiring adjacent land and constructing new blocks with shared infrastructure to achieve operating leverage. - Investment targeted to handle revenue growth beyond ₹4,000 crores and enable scaling towards ₹5,000 crores in the longer term. - Organic expansion in Europe, especially Germany, with operations starting in FY'26 including hiring employees and infrastructure setup. - Active pursuit of smaller M&A opportunities across Europe planned for 2026 to complement organic growth. - Investing in new geographies such as Canada and four European countries, balancing both organic and inorganic growth strategies. - No current plans to expand manufacturing capacity in the US; focus remains on leveraging low-cost Indian manufacturing base.

- The US business is expected to remain a major growth driver, with potential to double revenue in 4-5 years, aiming for around $300 million in 3 years, though geopolitical risks cause some caution. - The US market opportunity for private label OTC is several billion dollars; Marksans is among the top four players but far behind the market leaders. - Europe, especially Germany and four other key countries, is targeted for organic growth starting in 2026, with operations expected to scale in the second half of 2026. - UK market expected to double revenue within 5-7 years with new product launches and improving pricing environment. - CAPEX planned in 2026 (~Rs. 100 crores) to increase tablet capacity from 700-800 million to 1.2-1.3 billion tablets per month and triple soft gel capacity, enabling revenue growth beyond Rs. 4,000 crores. - Longer-term revenue target is Rs. 5,000 crores by FY 2030. - Overall growth rate historically ~20% plus; sustainable EBITDA margins targeted in 19-20%+ range as revenue scales.

- EBITDA margin expected to settle around 19% to 20% range in FY'26, with potential to be slightly better; north of 20% possible but 19%-20% is a safe assumption. - Operating leverage will improve as revenue grows, but initial investments in new markets and infrastructure may increase costs temporarily. - Revenue target to reach Rs. 3,000 crores by FY'27 and Rs. 5,000 crores by FY'30, indicating steady long-term growth. - EPS for H1 FY'26 at Rs. 3.5, with quarterly EPS of Rs. 2.2 in Q2 FY'26, showing growth alongside revenues. - Growth drivers include strong product pipelines in the U.S., U.K., and Europe, with expectations of improved margins through cost efficiencies and operating leverage. - Infrastructure expansion planned to support growth beyond Rs. 4,000 crores, including CAPEX of ~Rs. 100 crores in 2026 for capacity enhancement. - Overall, sustainable EBITDA margin improvement and revenue growth expected, supported by strategic investments and market expansion.

- Current U.S. order book stands between $225 to $230 million, indicating a strong position. (Page 4) - The company has ample manufacturing capacity, especially at the Teva plant, currently under 30% utilized, allowing for expansion without immediate capacity constraints. (Page 7) - Despite tariff uncertainties over the last six months, clarity has recently emerged, improving client confidence and order momentum. (Pages 7, 10) - The company is targeting an order book of $300 million within three years as part of its growth outlook. (Page 8) - Growth in other geographies such as Europe and Canada is also expected to contribute to the order pipeline in coming years. (Pages 6, 12)